Cargando…
Are off-target effects of imatinib the key to improving beta-cell function in diabetes?
The small tyrosine kinase (TK) inhibitor imatinib mesylate (Gleevec, STI571) protects against both type 1 and type 2 diabetes, but as it inhibits many TKs and other proteins, it is not clear by which mechanisms it acts. This present review will focus on the possibility that imatinib acts, at least i...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Open Academia
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487420/ https://www.ncbi.nlm.nih.gov/pubmed/36187072 http://dx.doi.org/10.48101/ujms.v127.8841 |